Leaflet BROXIVAN 6mg / ml oral solution

Product code:
W68932001
Quantity:
1
Indicated for:
respiratory disorders with viscous secretions
Route of administration:
oral
Substance:
ambroxol (mucolytic)
ATC
R05CB06 — Respiratory system | Expectorants, excl. combinations with cough suppressants | Mucolytics
Ambroxol is a mucolytic agent used to treat respiratory conditions characterized by excessive production of viscous mucus. It is indicated for acute and chronic bronchitis, asthma, chronic obstructive pulmonary disease (COPD), and other lung conditions involving difficulty in mucus clearance.

Ambroxol works by reducing mucus viscosity and stimulating the activity of cilia in the airways, facilitating expectoration. It is effective in relieving productive cough and improving breathing.

Additionally, ambroxol has anti-inflammatory and antioxidant properties, making it useful in reducing airway inflammation. In some cases, it is also used to alleviate sore throat pain due to its local anesthetic effect.

It is available in the form of tablets, syrup, oral solution, or inhalation, and is well-tolerated by most patients. Side effects are rare and may include nausea, stomach discomfort, or mild allergic reactions.

General data about BROXIVAN 6mg / ml

Substance:
ambroxol
Date of latest medicines list:
01-08-2022
Product code:
W68932001
Concentration:
6mg / ml
Pharmaceutical form:
oral solution
Quantity:
1
Product type:
Generic medicine
Prescription status:
OTC — Over the Counter = medicine that does not require a medical prescription.

Marketing authorisation

Manufacturer:
MEDOCHEMIE LTD, GOGOLS FACILITY - CIPRU
Holder:
MEDOCHEMIE LTD. - CIPRU
Number:
14168/2021/01
Shelf life:
2 years-after packaging for sale;after the first opening of the bottle-6 months

Concentrations available for ambroxol

  • 0.3%
  • 0.75%
  • 15mg
  • 15mg/5ml
  • 15mg/ml
  • 20mg
  • 30mg
  • 30mg/5ml
  • 3mg/ml
  • 50mg/g
  • 60mg
  • 6mg/ml
  • 7.5mg/ml
  • 75mg